Recently, Moriwaki et al. [135] reported that ﻿proteasome inhibitors MG132 and bortezomib can trigger the RIPK3/MLKL dependent necroptosis in both fibroblasts in mouse models and human leukemia cells. Here, MLKL is linked to leukemia.